explore -WSS

explore

author：focus 2025-09-29 11:38:20 - browse：65

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Pancreatic cancer early detection could be helped by AI

WSS

Boston competes with Raleigh

People with mental disorders often marry others with same

Pancreatic cancer early detection could be helped by AI

How generative AI ratchets up security threats for health systems

Humana’s losses in Medicare Advantage tank its stock

Republican states more likely to report Covid vaccine side effects

knowledge

explore

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Medicare drug price negotiation legal challenge met with skepticism

Medicare details structure of new drug price negotiation program

Multiple sclerosis has subtypes with different best treatments: study

How one medical school became remarkably diverse

Bird flu reported in person exposed to presumably infected cattle

Apple is now the first public company to be valued at $3 trillion

Vertex non

United colonoscopy coverage change 'may cost lives,' doctors say

Young boy dies in trial for Pfizer Duchenne gene therapy

knowledge

How generative AI ratchets up security threats for health systems

FTC sues over Novant Health acquisition of two N.C. hospitals

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Four alarming medical procedures we’re glad history forgot

Bernie Sanders is gearing up to subpoena pharma CEOs

Multiple sclerosis has subtypes with different best treatments: study

explore

focus

hotspot

entertainment